The company also remains on track with its more advanced familial adenomatous polyposis drug and plans to file within the next two weeks an investigational new drug application to begin testing the therapy in humans.
BD and Tyrian ended their partnership to develop a point-of-care diagnostic for active tuberculosis because of an inability to consistently detect Tyrian's lead protein biomarker in clinical samples at high enough sensitivity and specificity levels.
The company said it is working with the City of Hope to investigate the vector-based delivery of an anti-HIV RNA cocktail composed of pHIV7, an shRNA targeting an exon in HIV-1 tat/rev, and a Tar decoy.
Exiqon said that it has achieved several milestones in a collaboration with Tacere Therapeutics, including the completion of a series of customizable assays for the detection of therapeutic shRNAs currently under development through a partnership between Tacere and Pfizer.
The $600,000 award also strengthens Inviragen's ties to UW-Madison. The company's CSO maintains an academic appointment and a research lab within the School of Veterinary Medicine, which has collaborated with Inviragen on other projects.
In an interview with Pharmacogenomics Reporter this week, Hakan Sakul provided a snapshot of Pfizer's efforts in personalized medicine, the company's stance on regulatory issues, and its overall focus on "omics"-guided medicine.